Peptides DB
Research-centric peptide and protocol reference hub
Study 19 of 20Glutathione (GSH) literatureThe Lancet. Global healthTop journal2026

Cost-effectiveness of providing pre-exposure and post-exposure prophylaxis for the prevention of HIV via online pharmacies in western Kenya: a modelling study.

Online PrEP and PEP could significantly reduce HIV infections in western Kenya, with a cost-effectiveness ratio of $212 per DALY averted.

Read at The Lancet. Global healthAdd to compare

Where it sits

this study against the rest of the glutathione (gsh) corpus
1
Preclinical · this one
15
Observational
0
Open-label
2
Randomised
2
Reviews

Summary and findings

This study estimated the cost-effectiveness of providing online pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) for HIV prevention in western Kenya. The model projected that online PrEP and PEP could avert 13.9% of HIV infections over 10 years. The intervention was deemed cost-effective with an incremental cost-effectiveness ratio (ICER) of $212 per disability-adjusted life-year (DALY) averted.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
$212 per DALY averted.2026

Abstract

The authors’ words, as The Lancet. Global health supplied them

<h4>Background</h4>Oral pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) provision via online pharmacies (henceforth online PrEP and PEP) offers promise in increasing biomedical HIV prevention coverage. In this study, we aimed to estimate the cost-effectiveness of online PrEP and PEP scale-up in western Kenya.<h4>Methods</h4>We adapted a network-based model, EMOD-HIV, to simulate online PrEP and PEP implementation from 2026 to 2036; costs and use of online PrEP and PEP and client characteristics were informed by the ePrEP Kenya pilot study, which evaluated online PrEP and PEP provision in Nairobi and Mombasa, Kenya. Other parameters were obtained from surveillance data and published literature. Eligible clients were aged 15-49 years reporting condomless sex with non-marital partners. We assumed online PrEP and PEP provision was implemented through public-private partnership, with the Kenya Ministry of Health providing PrEP and PEP drugs and service delivery costs paid by the online pharmacy (and charged to clients). We estimated HIV infections, HIV-related deaths, and disability-adjusted life-years (DALYs) averted compared with the baseline scenario of background oral PrEP only. We calculated incremental cost-effectiveness ratios (ICERs) assessing only costs incurred by the Kenya Ministry of Health over 35 years and used a supply-side threshold of US$500 per DALY averted. We calculated 95% uncertainty intervals (UIs) across 100 parameter sets.<h4>Findings</h4>Online PrEP and PEP was projected to reach population coverage of 0·7% (95% UI 0·7-0·8) for PEP and 0·3% (0·2-0·3) for PrEP and avert 13·9% (10·1-17·1) of HIV infections over 10 years. HIV-related deaths were reduced by 4·3% (95% UI 2·0-6·9) over the 35-year time horizon. The intervention was cost-effective from the Kenya Ministry of Health perspective (ICER $212 [95% UI 15-1409] per DALY averted). In a scenario assuming only online PEP availability (to isolate the effect of PEP), 11·6% (95% UI 8·6-15·2) of HIV infections were averted (ICER $210 [95% UI 41-3798] per DALY averted). The intervention remained cost-effective when varying PrEP and PEP effectiveness and assuming HIV testing and treatment disruptions.<h4>Interpretation</h4>Online PrEP and PEP can avert substantial HIV infections, even with low population coverage. PEP was responsible for most intervention health benefits, likely due to high observed demand for PEP compared with PrEP in the pilot study. Leveraging private retailers can be efficient for scaling up HIV prevention in an era of shrinking donor funding.<h4>Funding</h4>Gates Foundation.

Elsewhere in the Glutathione (GSH) corpus

ALidocaine Spray Versus Viscous Lidocaine Solution Plus Lidocaine Spray in Patients Undergoing Non-Sedated Esophagogastroduodenoscopy: A Randomized Controlled Trial.DEN open · 2026 · mean VAS 1.6 ± 1.1 vs. 3.1 ± 1.7; p = 0.01HumanCPEPTIDE IDR-1002 REGULATES THE ANTIOXIDANT AND ANTI-INFLAMMATORY RESPONSES BY ACTIVATING THE KEAP1-NRF2 SIGNALING PATHWAYbiorxiv-preprint · 2026 · EC50 of 18.57 μM for Nrf2-mediated transcriptional activity.In vitroCOphthalmate tripeptide is a signaling molecule that regulates striatal neurotransmissionbiorxiv-preprint · 2026 · Not reported in abstract.AnimalBImproved Efficiency and Lesion Detection in Small Bowel Capsule Endoscopy Using the Open-Source Artificial Intelligence Model SEE-AI.DEN open · 2023 · n=249 · Per-lesion sensitivity: 98.8% (1532/1550) for AI vs 86.4% (1339/1550) for conventional reading, p<0.0001.HumanBPatient Characteristics Associated With Preference for 480-mL Oral Sodium Sulfate: A Prospective Clinical Study on Bowel Cleansing Efficacy and Taste Acceptability for Total Colonoscopy.DEN open · 2023 · n=263 · 98% achieved satisfactory cleansing (BBPS ≥ 6) among 263 patients.HumanBOptimal Stenting Strategy During Chemotherapy: Impact of Time to First Reintervention on Survival in Malignant Hilar Biliary Obstruction.DEN open · 2023 · n=81 · TTFR correlated with overall survival (r = 0.60, p < 0.01).Human